Kyle Baker, MD
Obstetrics & Gynecology · New Britain, CTNPI 1922078948
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 347 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,190 and has fallen 59.8% since, to $478 in 2025. Among obstetrics & gynecology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 347 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Astellas Pharma US Inc$881
- Exeltis, USA Inc.$548
- Sumitomo Pharma America, Inc.$447
- Coopersurgical, Inc.$359
- Agile Therapeutics, Inc.$319
- plus $3K from 31 others
What the payments were for
- Consulting fees$431%
- Food & beverage$6,26895%
- Education$2975%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 75 | $1,412 |
| Astellas Pharma US Inc | 36 | $881 |
| Exeltis, USA Inc. | 26 | $548 |
| Sumitomo Pharma America, Inc. | 23 | $447 |
| Coopersurgical, Inc. | 18 | $359 |
| Agile Therapeutics, Inc. | 16 | $319 |
| Avion Pharmaceuticals | 29 | $309 |
| Merck | 13 | $234 |
| Therapeuticsmd, Inc. | 12 | $212 |
| Mayne Pharma Commercial LLC | 9 | $188 |
| Lupin Inc. | 10 | $159 |
| Exact Sciences | 7 | $153 |
| Mylan Pharmaceuticals Inc. | 9 | $139 |
| Bayer | 8 | $136 |
| Myovant Sciences Inc. | 8 | $135 |
| Pfizer | 7 | $124 |
| Organon | 4 | $94 |
| AMAG Pharmaceuticals, Inc. | 4 | $77 |
| Urovant Sciences Inc | 4 | $75 |
| Duchesnay USA Incorporated | 3 | $71 |
| Sage Therapeutics, LLC | 3 | $70 |
| Millicent US Inc | 4 | $70 |
| Aspira Women's Health Inc | 2 | $61 |
| Scynexis, Inc. | 2 | $46 |
| Roche Diagnostics Corporation | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Smith+Nephew | 1 | $27 |
| Avanos Medical | 1 | $25 |
| Mission Pharmacal Company | 1 | $23 |
| GE HealthCare | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
| Conmed Corporation | 1 | $18 |
| Evofem Biosciences, Inc. | 1 | $17 |
| Monaghan Medical Corporation | 1 | $13 |
| Hologic Sales And Service, LLC | 1 | $12 |
How this compares
$6,609 in reported general payments places this provider in the 95th percentile of 605 obstetrics & gynecology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 41 | $41,009 |
| PremarinEstrogens, Conjugated | 31 | $14,267 |
| Estradiol | 52 | $4,638 |
| YuvafemEstradiol | 27 | $3,282 |
| ValacyclovirValacyclovir Hcl | 37 | $1,415 |
| Ibandronate Sodium | 20 | $756 |
| Nystatin | 40 | $563 |
| Metronidazole | 12 | $544 |
| Clobetasol Propionate | 28 | $508 |
| Fluconazole | 96 | $501 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 28 | $404 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 26 | $315 |
| Triamcinolone Acetonide | 21 | $76 |
| Alendronate Sodium | 18 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $447 | $41,00941 claims |
| PfizerPremarin | $124 | $14,26731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 605 obstetrics & gynecology providers in Connecticut.
Other obstetrics & gynecology in New Britain
- Gerard RoyNew Britain$6K
- Stephanie GarozzoNew Britain$5K
- Lisa RinaldiNew Britain$5K
- Mary MinkinNew Haven$285K
- Alessandro SantinNew Haven$98K
- Frederick RauHartford$89K
- Peter AuerbachGroton$41K
- Shieva GhofranyStamford$33K
- Mark LeondiresNorwalk$31K
- Alan FineHartford$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.